MedTrace Logo

Conservative Management of CIN2 Lesions and Biomarkers Evaluation

NCT04687267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 319

Last updated 2023-09-28

No results posted yet for this study

Summary

Prospective study including women aged 25-45 years, adherent to the cervical screening program of four different centers of the Veneto region, with a diagnosis of CIN2 lesion. After enrollment according to predefined criteria, and informed consent to participate, the CIN2 lesions are managed by follow-up; cases with progressive lesions will be treated immediately, cases with CIN2 persistence for more than 12 months will be treated as well. Viral, molecular and immunocytochemical biomarkers will be studied, and evaluated in relation to the clinical outcome.

Conditions

  • CIN2

Sponsors & Collaborators

  • Azienda ULSS 3 Serenissima

    collaborator OTHER

  • Azienda Ulss 6 Euganea

    collaborator OTHER

  • Azienda Ulss 2 Marca Trevigiana

    collaborator OTHER

  • Azienda Ulss 9 Scaligera

    collaborator OTHER_GOV

  • Regione Veneto

    collaborator OTHER

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Tiziano Maggino, MD · Azienda ULSS 3 Serenissima

Eligibility

Min Age
25 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-15
Primary Completion
2021-10-31
Completion
2022-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04687267 on ClinicalTrials.gov